Skip to Main Content

Chapter 52. Benign Prostatic Hyperplasia

A uroselective α-adrenergic antagonist inhibits this α-adrenergic receptor in prostatic smooth muscle?

A. α1A

B. α1D

C. α1B

D. α2A

E. α2B

Use of a 5α-reductase inhibitor can be expected to reduce the volume of an enlarged prostate gland by this percentage.

A. 10

B. 20

C. 50

D. 75

E. 100

Use of an α-adrenergic antagonist or a 5 α-reductase inhibitor can be expected to have this clinical effect in patients with symptomatic BPH:

A. Decrease peak urinary flow rate

B. Increase postvoid residual urine volume

C. Increase detrusor relaxation

D. Improve bladder emptying

E. Increase urinary frequency

Which of these agent(s) has/have a low likelihood of causing cardiovascular adverse effects in a patient with BPH who also is receiving antihypertensives for essential hypertension?

1. Alfuzosin

2. Tamsulosin

3. Silodosin

A. 1 only

B. 2 only

C. 3 only

D. 1 and 3 only

E. 1, 2, and 3

Which one of the following statements about tadalafil’s use for LUTS is correct?

A. It should be dosed on demand or when needed.

B. It is indicated for patients with complications of BPH.

C. It works by causing relaxation of the detrusor muscle.

D. It produces an increase in peak urinary flow rate.

E. It reduces the AUA symptom score by at least 3 points.

The benefits of combination treatment with a 5α -reductase inhibitor and α-adrenergic antagonist for BPH includes all of the following except:

A. Increasing urinary flow rate


Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.